Full Year 2026 Mayne Pharma Group Ltd Earnings Call Transcript
Key Points
- Gross margin expanded to 64.7%, up 411 basis points, with gross profit essentially flat despite lower revenue.
- DistributeRx launch exceeded expectations, with strong prescription growth and a major facility expansion to increase capacity sevenfold.
- FDA removed the black box warning on BIJUVA, boosting its sales by 20% and supporting the growing menopause market.
- Nextellis secured PBS approval in Australia, driving strong prescription growth and expanding covered lives by approximately 15 million.
- Dermatology segment saw an 11% increase in direct contribution, driven by a shift to higher-margin branded products.
- Group revenue declined 6% to $383.7 million, impacted by unfavorable foreign exchange and competitive erosion.
- Underlying EBITDA fell 27% to $34.2 million, reflecting business disruption and increased costs.
- Women's Health segment faced $11 million in product returns for Annovera, negatively impacting revenue and profit.
- International segment direct contribution dropped 38% due to higher operating expenses and portfolio transition.
- Legal and litigation costs from the Cosette transaction continue, with an appeal pending and ongoing damages claim.
Thank you for standing by and welcome to the Maine Pharma Group Limited full-year 2026 results. (Operator Instructions)
I'd now like to hand the conference over to Mr. Aaron Gray, CEO. Please go ahead.
Thank you, operator. Good morning, everyone, and thank you for joining Maine Pharma's fiscal year '26 full-year results presentation. I'm Aaron Gray, Chief Executive Officer, and I'm joined today by Griffin Buchanan, our Chief Financial Officer, who was appointed in August.
Today, I'll begin with our fiscal '26 corporate highlights and global footprint. Griffin will then take you through the group financial performance before I return to walk through each of the three segments, Women's Health. Dermatology and DistributeRx and International and we'll then close with our future growth drivers and fiscal year '27 focus and outlook. Then we will open the line for questions.
Please take a moment to read the disclaimer regarding forward-looking statements and the use of non-IFRS
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
